Group 1 - The core viewpoint of the article highlights that CSPC Pharmaceutical Group (01093) has seen a stock price increase of approximately 9% year-to-date, with a notable rise of 14% prior to the announcement of its collaboration with AstraZeneca on January 30 [1] - HSBC Research has raised its revenue forecasts for CSPC for the years 2025 to 2027 by 3% to 11%, considering prepayments and slight improvements in sales from the previous quarter [1] - The net profit forecasts for CSPC for the years 2025 to 2027 have been increased by 7% to 18%, indicating that growth in external licensing revenue can offset the negative impacts of centralized procurement policies [1] Group 2 - Citi has indicated that the business development (BD) transactions completed by CSPC are expected to convert into recurring revenue starting this year [1] - CSPC's significant BD deals with AstraZeneca and Madrigal Pharmaceuticals are projected to generate approximately $10.2 billion in upfront and milestone payments, significantly boosting profits to 6.3 billion, 10.2 billion, and 10.9 billion RMB for the years 2025 to 2027 [1]
港股异动 | 石药集团(01093)涨超3% 机构看好公司未来在EGFR ADC及研发平台将有...